Abstracts

CHARACTERIZING “EXCEPTIONAL” CONTROL AMONG HIV ELITE CONTROLLERS

Studies of “elite controllers” (ECs) might lead to novel approaches for HIV cure. We characterized the clinical, immunologic and virologic characteristics of ECs with very low reservoirs (“exceptional controllers”). Such individuals may prove to be models for a functional cure. We systematically applied a clinical case definition to identify ECs within the SCOPE cohort. A…

PULMONARY TUBERCULOSIS DISEASE ENHANCES HIV-1 ANTIBODY RESPONSES

Mycobacterium tuberculosis (TB) is an integral component of complete Freund’s adjuvant which is known to augment antibody production. We hypothesized that active TB disease enhances the development of HIV-1 broadly neutralizing antibodies (bnAbs) in people living with HIV-1. We compared anti-HIV-1 antibody response among treatment-naive plasma samples from 15 HIV-1 patients with active pulmonary TB (HIV-1/TB) and…

IMPACT OF IMMUNE CHECKPOINT INHIBITORS IN VACCINE-INDUCED ANTI-HIV RESPONSES

To attain the control or elimination of HIV-1 infection it is critical to delineate immune interventions capable of boosting or reinvigorating HIV-1-specific CD8+ T-cell responses. Immune interventions, including therapeutic vaccines or immune checkpoint inhibitors (ICIs), have been postulated to achieve this goal. However, the potency of combining both immune interventions has not yet been tested.…

POLY/AUTOREACTIVITY AND BROAD NEUTRALIZATION ARE DETERMINED BY DIFFERENT MUTATIONS

Nearly half of broadly neutralizing antibodies (bnAbs) are polyreactive and/or autoreactive (poly/autoreactive). Some of them, like CH103, gain poly/autoreactivity during bnAb maturation. However, whether poly/autoreactivity and broad neutralization are governed by the same mutations during bnAb maturation is not well understood. Mutations in Ab pairs differing in poly/autoreactivity within the CH103 lineage were individually introduced…

UNCOUPLED CELLULAR AND PLASMA MARKERS OF MONOCYTE ACTIVATION IN EARLY HIV INFECTION

Monocytes are chronically activated in HIV infection, showing increased expression of CD16 and downregulation of CD14. This observation is concomitant to increased plasma levels of sCD14 and sCD163, which are considered surrogate markers of monocyte activation. Nevertheless, phenotypic abnormalities of monocytes during primary HIV infection (PHI) are not fully characterized. We longitudinally studied monocytes in…

VH GENE POLYMORPHISM ASSOCIATED WITH POTENT ANTI-SIV NEUTRALIZING ANTIBODY INDUCTION

Induction of potent broadly-neutralizing antibodies (bNAbs) is a key for anti-HIV vaccine development. The boosting method for B-cell maturation toward bNAb induction has not been established, although recent studies have developed germline-targeting immunogens for priming. Here, we present a unique macaque model to analyze B-cell responses leading to anti-simian immunodeficiency virus (SIV) bNAb induction. In…

IDENTIFICATION OF BROADLY NEUTRALIZING ANTIBODIES FROM SHIV-INFECTED CHINESE MACAQUES

Broadly neutralizing antibodies (bnAbs) have been obtained from HIV-1-infected individuals after 2-4 years of infection. However, bnAbs with similar breadth and potency have not been isolated from SHIV-infected rhesus macaques. Understanding how bnAbs develop in SHIV-infected non-human primates (NHPs) will have important implications in use of rhesus macaques to study efficacy of HIV-1 vaccines. Single…